OmniPathology is a leader in women’s health. Through partnerships with industry leaders such as Hologic, Abbott, BD and Roche, we are offering the most comprehensive testing menu that services gynecological practices that includes cutting edge diagnostic testing. Our menu allows us to provide early detection of various GYN conditions. It includes reflex molecular testing and genotyping of HPV performed on PAP samples and additional esoteric testing for cervical cancer and premalignant conditions. We offer the latest technology of image analysis and computer assisted diagnostics.

Our pathologists are board certified in pathology and cytopathology and are specialized in GYN pathology. Our protocols and strict quality standards enable our team to provide our physicians with comprehensive, accurate and reliable results.

GYNECOLOGICAL PATHOLOGY

Comprehensive Testing

    • Cervical pap (Thin-Prep)

      ∘ Anal pap (Thin-Prep)

      ∘ Oral/Throat Brushings (Thin-Prep)

      ∘ Biopsies: Endocervical, Cervical, Endometrial, Cervical LEEPs

    • Pap smears

      ∘ TERC FISH for acquired cytogenetic changes associated with anal squamous cell carcinoma

    • Molecular Testing:

      ∘ HPV molecular testing with subtyping

      ∘ Chlamydia-Gonorrhea-Trichomonas

    • Vaginosis Panel: Bacterial and Candida infections

    • Histopathology:

      ∘ Cervical and endometrial

      ∘ Products of conception

      ∘ Immunohistochemistry staining (p16 and Ki67)

      ∘ HPV Subtyping by In-Situ Hybridization (ISH) on cervical and anal biopsies’

    • Florescent in-situ hybridization (FISH)

      ∘ C-MYC FISH ✦NEW✦

      ➥ Over-treatment of CIN1 lesions can have negative impact on young women and potential adverse pregnancy outcomes.

      ➥ CIN1 Patients with high c-MYC copy numbers show significantly increased risk of persistent and progressive dysplasia. *Kübler et al, 2014

      ➥ This allows treatment to be based on the biological and behavioral diversity of the lesions.

      ∘ TERC FISH

      ➥ TERC FISH assay, through comparison of TERC and 3p telomere fluorescent signals, is designed to help differentiate between normal/low-grade dysplasia and high-grade dysplasia/carcinoma.

      ➥ 3q26 (TERC) detected gains in 80% of cervical intraepithelial neoplasia grade 2-3 (CIN2-3) cases and in 100% of squamous cell carcinoma (SCC) cases. **Policht et al, 2010

      ➥ TERC FISH complements cytomorphological assessment.

    • The Expected turn-around-time (TAT) for this test is 24 hours (Molecular testing and additional studies will increase TAT by 24-48 hours)

    • A detailed easy to read report with images is faxed to your office

    • The tests are covered by all major insurances

    • Omni offers reasonable cash price for the test for uninsured patients. Call 626-744-5339 for information

QUESTIONS?